secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001193125-24-275595
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia sells Rare Pediatric Disease PRV for $150M, one third to partner Neuren
------------------------------------------------------------------------------

- Closed sale of PRV for $150M on Dec 11, 2024, after HSR waiting period expired.
- PRV awarded March 2023 from FDA approval of DAYBUE (trofinetide) for Rett syndrome.
- One third of net proceeds payable to Neuren under July 2023 joint venture agreement.
- Material terms of PRV Transfer Agreement previously disclosed in Q3 2024 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524275595/0001193125-24-275595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524275595/d841090d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-275595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer